Rabbit Polyclonal GRIA2 Antibody

The GRIA2 antibody targets the GluA2 subunit of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, a critical ionotropic glutamate receptor in the central nervous system. Encoded by the GRIA2 gene, GluA2 is essential for AMPA receptor assembly, trafficking, and synaptic plasticity. Unlike other AMPA receptor subunits, GluA2 typically reduces calcium permeability due to RNA editing at the Q/R site, influencing neuronal excitability and synaptic signaling. Dysregulation of GluA2 expression or function is implicated in neurological disorders such as epilepsy, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), and ischemic brain injury. GRIA2 antibodies are widely used in neuroscience research to detect GluA2 protein levels, localization, and post-translational modifications (e.g., phosphorylation) in brain tissues or cellular models. They enable studies on synaptic receptor composition, receptor trafficking mechanisms, and disease-associated alterations. Commercial GRIA2 antibodies are often validated for techniques like Western blot, immunohistochemistry, and immunofluorescence, with specificity confirmed through knockout controls. Recent research also explores GluA2's role in neuroprotection and its potential as a therapeutic target, emphasizing the antibody's utility in elucidating AMPA receptor-related pathophysiology and drug development.